Comfort Kunak Ogar

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque-Pereira, Christine Leopold et autres

AIM: Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine-derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other …

nl, us (code pays fourni par la source)

Pharmacovigilance capacity and readiness of vaccine manufacturers in low- and middle-income countries: a maturity-based assessment of the pharmacovigilance system

Patrícia Mouta Nunes de Oliveira, Reza Bosman, Maria Beatriz Bastos Lucchesi, Comfort Kunak Ogar et autres

br, us, ch (code pays fourni par la source)

Correction: Advancing Pharmacovigilance Practice in Africa: Moving from Data Collection to Data-Driven Decision Making—Report from the 4th ISoP Africa Chapter Meeting

Helen Byomire Ndagije, Sheila Ampaire, George Tsey Sabblah, Comfort Kunak Ogar et autres

In this article the meeting number was incorrectly given as '5th ISoP Africa Chapter Meeting' but should have been '4th ISoP Africa Chapter Meeting'The affiliation details for George Tsey Sabblah were incorrectly given as 'Pharmacovigilance Division, Ghana Food and Drug Administration, Accra, …

Ouganda, be, Ghana, us, Kenya, nl, Érythrée, Éthiopie, Nigéria, no, Afrique du Sud, co (code pays fourni par la source)

Advancing Pharmacovigilance Practice in Africa: Moving from Data Collection to Data-Driven Decision Making—Report from the 4th ISoP Africa Chapter Meeting

Helen Byomire Ndagije, Sheila Ampaire, George Tsey Sabblah, Comfort Kunak Ogar et autres

The International Society of Pharmacovigilance (ISoP) is a professional, independent non-profit society, open to anyone with an interest in patient safety and effective use of medicinal products [ 1 ]. Through its regional chapters, ISoP supports management of region-specific pharmacovigilance (PV) challenges. …

us, Ouganda, be, Ghana, Kenya, nl, Érythrée, Éthiopie, Nigéria, no, Afrique du Sud, co (code pays fourni par la source)

Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases

Leonardo Roque Pereira, Malede Mequanent Sisay, Comfort Kunak Ogar, Carlos E. Durán et autres

BACKGROUND: Although multiple post-licensure studies demonstrated that coronavirus disease-2019 (COVID-19) vaccines are safe for use during pregnancy, none of them have identified a signal of disproportionate reporting. AIM: To assess the disproportionality in reported adverse events among pregnant persons receiving COVID-19 vaccination …

nl (code pays fourni par la source)

Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021

Omotayo O. Bolu, Oluwafemi David Alo, Emem Iwara, Ashley T Longley et autres

us, Ouganda, Nigéria (code pays fourni par la source)

Pharmacovigilance Capacity and Readiness of Vaccine Manufacturers in Low- and Middle-Income Countries: A Maturity-Based Assessment of the Pharmacovigilance System

Patrícia Mouta Nunes de Oliveira, Reza Bosman, Maria Beatriz Bastos Lucchesi, Comfort Kunak Ogar et autres

br (code pays fourni par la source)

Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study

Delese Mimi Darko, Seth Kwaku Seaneke, Eric Karikari-Boateng, Edwin Nkansah et autres

INTRODUCTION: The development of COVID-19 vaccines during the pandemic occurred with an unprecedented speed, requiring extraordinary post-approval safety monitoring to facilitate ongoing evaluation of their benefit-risk profile. In Ghana, the Food and Drugs Authority granted emergency use authorization to six of these …

Ghana, us, nl (code pays fourni par la source)

Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study

Comfort Kunak Ogar, Hannah N. Gilbert, Lourens T. Bloem, Christine Leopold et autres

nl, us, Nigéria (code pays fourni par la source)

Patient-Reported Outcomes of Adverse Events after Covid-19 Vaccination in Nigeria: A Mixed Methods Study

Comfort Kunak Ogar, Hannah N. Gilbert, Lourens T. Bloem, Christine Leopold et autres

nl, us, Nigéria, Bénin (code pays fourni par la source)

The Role of ISoP in the Advancement of Pharmacovigilance in Low-and Middle-Income Countries (LMICs)

Mohamed A. Elhawary, Comfort Kunak Ogar, Mónica Tarapués, Angela Caro-Rojas et autres

Égypte, nl, co, Ouganda (code pays fourni par la source)

Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy

Annette K. Regan, Deshayne B. Fell, Lauren Anne Wise, Gabriela Vazquez‐Benitez et autres

us, ca, no (code pays fourni par la source)